LIVE
ABBV
AbbVie Inc. · Pharmaceuticals
$216.49
+1.28% this month
VERSUS
⟷
COMPARE
JNJ
Johnson & Johnson · Pharmaceuticals / Medical Devices
$228.39
-0.70% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
ABBV
4
JNJ
1
Comparison scoreboard
ABBV LEADS 4/5AI Score
ABBV ✓52.0
JNJ 48.7
1Y Return
ABBV +16.72%
JNJ ✓+49.88%
Fwd P/E
ABBV ✓14.01
JNJ 18.94
Target Up.
ABBV ✓+11.34%
JNJ +4.98%
Op. Margin
ABBV ✓32.16%
JNJ 27.41%
Metrics last refreshed: 6/20/2026
Quick take
ABBV vs JNJ Stock Comparison: AI Score, Valuation, Performance and Upside
ABBV and JNJ are both large-cap pharma Dividend Aristocrats/Kings facing significant patent cliffs (Humira for AbbVie, Stelara for J&J) while executing next-generation growth strategies. AbbVie's entire identity is Skyrizi and Rinvoq replacing Humira's $20B peak revenue. J&J's diversification across pharma and medical devices provides more resilience. AbbVie's 4% dividend yield is higher than J&J's. Both are quality healthcare income investments with different execution risk profiles.
ABBV vs JNJ — AbbVie (the immunology-focused pharmaceutical company replacing Humira's $20B peak revenue with Skyrizi and Rinvoq immunology drugs while leveraging Allergan's Botox franchise) versus Johnson & Johnson (the pharma + medical device Dividend King with Darzalex oncology dominance, DePuy Synthes orthopedics, and 60+ consecutive years of dividend growth).
Live analysis · updated 6/20/2026
ABBV holds the edge across 4 of 5 key metrics in this comparison. JNJ has delivered stronger 1-year price return (+49.88% vs +16.72%), though ABBV trades at the lower forward P/E (14.01x vs 18.94x). ABBV leads on both revenue growth (12.40%) and operating margin (32.16%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for ABBV (+11.34%) than for JNJ (+4.98%).
Normalized 1Y performance
ABBV
JNJ
Recent returns
ABBV
JNJ
Analyst price targets & sentiment
ABBV · 27 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.0/5.0)
Price target range
analyst low$170.00
analyst mean$253.55
current price$216.49
+11.3% upside to analyst mean
JNJ · 23 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.3/5.0)
Price target range
analyst low$150.00
analyst mean$252.87
current price$228.39
+5.0% upside to analyst mean
Who should consider this stock?
ABBV may suit investors who:
- →believe Skyrizi and Rinvoq will collectively exceed Humira's $20B peak sales — if immunology market expansion materializes, AbbVie's revenue story is exceptionally positive despite the Humira cliff
- →value AbbVie's 4% dividend yield as the highest among major pharmaceutical Dividend Aristocrats — income investors seeking pharma yield prefer AbbVie's above-sector yield
- →see Botox as a unique diversification asset — the aesthetics market is resilient and the therapeutic neurotoxin portfolio (migraine, overactive bladder) creates a non-immunology growth vector
- →are comfortable with Humira biosimilar revenue decline, Allergan acquisition debt, and Rinvoq JAK inhibitor safety label risk
JNJ may suit investors who:
- →want the most diversified large healthcare company combining pharma (Darzalex, oncology) and medical devices (orthopedics, cardiac) for broader portfolio risk distribution
- →value J&J's Dividend King status (60+ years) as the most iconic healthcare income track record with the longest consecutive growth streak among healthcare majors
- →see Darzalex's $10B+ peak sales potential and ongoing label expansion as a durable multi-year oncology revenue contributor
- →are comfortable with Stelara biosimilar revenue decline, talc litigation financial uncertainty, and Tremfya competing in an immunology market where AbbVie's Skyrizi is currently outpacing J&J
Performance & AI score
| Metric | ABBV | JNJ |
|---|---|---|
| AI score | 52.0 | 48.7 |
| AI rank | #346 | #544 |
| Latest close | $216.49 | $228.39 |
| 1M return | +1.28% | -0.70% |
| 6M return | -3.49% | +8.59% |
| 1Y return | +16.72% | +49.88% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ABBV | JNJ |
|---|---|---|
| 1Y ago | $11.67K (+16.7%) started 2025-06-18 | $15.15K (+51.5%) started 2025-06-18 |
| 5Y ago | $26.07K (+160.7%) started 2021-06-21 | $17.38K (+73.8%) started 2021-06-21 |
| 10Y ago | $83.39K (+733.9%) started 2016-06-20 | $32.67K (+226.7%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | ABBV | JNJ |
|---|---|---|
| Market cap | $402.35B | $579.83B |
| Trailing P/E | 111.09 | 27.94 |
| Forward P/E | 14.01 | 18.94 |
| Price/Sales | 5.85 | 4.18 |
| EV/Revenue | 7.42 | 6.36 |
| Analyst target | $253.55 | $252.87 |
| Target upside | +11.34% | +4.98% |
Growth, profitability & risk
| Metric | ABBV | JNJ |
|---|---|---|
| Revenue growth | 12.40% | 9.90% |
| Earnings growth | -46.20% | -52.90% |
| EPS growth | -46.20% | -52.90% |
| FCF margin | +33.13% | +12.98% |
| Operating margin | 32.16% | 27.41% |
| Profit margin | 5.79% | 21.83% |
| ROIC proxy | 6225.00% | 26.42% |
| Return on equity | 6225.00% | 26.42% |
| Dividend yield | 3.04% | 2.23% |
| Beta | 0.31 | 0.26 |
| Debt/equity | 4789.60 | 67.73 |
| Current ratio | 0.80 | 1.02 |
| Quick ratio | 0.52 | 0.69 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
ABBV max drawdown19.23%
JNJ max drawdown10.96%
ABBV max wkly drop8.49%
JNJ max wkly drop5.81%
5Y risk snapshot
ABBV max drawdown21.92%
JNJ max drawdown18.41%
ABBV max wkly drop17.30%
JNJ max wkly drop9.18%
10Y risk snapshot
ABBV max drawdown45.09%
JNJ max drawdown27.37%
ABBV max wkly drop19.39%
JNJ max wkly drop13.25%
Performance metrics by period
| Period | Metric | ABBV | JNJ |
|---|---|---|---|
| 1Y | Growth | +16.71% | +51.52% |
| CAGR | +16.74% | +51.61% | |
| Sharpe ratio | 0.57 | 2.26 | |
| Max drawdown | 19.23% | 10.96% | |
| Max daily drop | 5.20% | 2.48% | |
| Max wkly drop | 8.49% | 5.81% | |
| 5Y | Growth | +120.43% | +55.21% |
| CAGR | +17.16% | +9.20% | |
| Sharpe ratio | 0.61 | 0.34 | |
| Max drawdown | 21.92% | 18.41% | |
| Max daily drop | 12.57% | 7.59% | |
| Max wkly drop | 17.30% | 9.18% | |
| 10Y | Growth | +426.67% | +149.24% |
| CAGR | +18.09% | +9.57% | |
| Sharpe ratio | 0.60 | 0.34 | |
| Max drawdown | 45.09% | 27.37% | |
| Max daily drop | 16.25% | 10.04% | |
| Max wkly drop | 19.39% | 13.25% |
Business comparison
| Category | ABBV | JNJ |
|---|---|---|
| Company | AbbVie Inc. | Johnson & Johnson |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | AbbVie (spun from Abbott in 2013) is the world's leading immunology company famous for Humira — the world's best-selling drug for 10 consecutive years treating rheumatoid arthritis, psoriasis, and Crohn's disease. Humira's US patents expired in 2023, creating a significant revenue cliff. AbbVie's next-generation immunology drugs Skyrizi (interleukin-23 inhibitor) and Rinvoq (JAK inhibitor) are the company's primary growth pillars replacing Humira revenue. AbbVie acquired Allergan in 2020 for $63B, adding Botox (aesthetics, neurotoxin therapeutics), Linzess, Vraylar, and other specialty pharmaceutical brands. | Johnson & Johnson post-Kenvue spinoff focuses on pharmaceuticals (Janssen) and medical devices (DePuy Synthes, Abiomed, surgical robotics). J&J's pharma portfolio is led by Darzalex (multiple myeloma), Stelara (psoriasis/Crohn's), Erleada (prostate cancer), and Tremfya (psoriasis). The medical devices division provides orthopedic implants, cardiac devices, and surgical tools. J&J's Janssen division competes directly with AbbVie in immunology — Tremfya (IL-23 inhibitor) competes with AbbVie's Skyrizi in psoriasis. J&J is a Dividend King with 60+ years of consecutive dividend increases. |
| Investor focus | Investors focus on Skyrizi and Rinvoq combined peak sales potential (expected to exceed Humira's peak), Botox aesthetics recovery, AbbVie's oncology and neuroscience pipeline, and Humira biosimilar impact management. | Investors focus on Darzalex growth and patent life, Stelara biosimilar impact (significant revenue loss underway), new drug launches (Rybrevant + lazertinib, nipocalimab), and talc litigation resolution. |
ABBV strengths
- →Skyrizi and Rinvoq replacing Humira: Skyrizi (risankizumab) and Rinvoq (upadacitinib) are approved across multiple immunology indications and are on trajectory to collectively exceed Humira's $20B peak sales by 2027
- →Botox franchise: Botox is a unique franchise in both aesthetics (wrinkle reduction) and therapeutic neurotoxin (chronic migraine, cervical dystonia, overactive bladder) — a deeply defensible brand with decades of safety and efficacy data
- →Strong dividend: AbbVie is a Dividend Aristocrat with 50+ consecutive years of dividend increases (including Abbott's history) — paying approximately 4% yield with strong FCF coverage
JNJ strengths
- →Darzalex global oncology dominance: Darzalex leads multiple myeloma treatment globally with continued label expansion and combination regimen adoption
- →Medical devices providing non-pharma diversification: DePuy Synthes (orthopedic implants), Abiomed (ventricular assist devices), and surgical robotics provide revenue diversification beyond pharmaceutical pipeline risk
- →Dividend King with 60+ year increase streak: J&J's 60+ consecutive annual dividend increases make it one of the most reliable income growth stocks in healthcare
Risks to watch — ABBV
- →Humira biosimilar revenue decline: Humira US revenue is declining sharply as biosimilars capture market share — AbbVie must execute Skyrizi and Rinvoq growth to offset the $10B+ US Humira revenue decline
- →Allergan acquisition debt: the $63B Allergan acquisition added significant debt — high leverage limits M&A flexibility while Humira revenues are declining
- →JAK inhibitor safety label expansion risk: Rinvoq (JAK inhibitor) carries FDA warnings for serious infection, malignancy, and cardiovascular risk — expanding indications faces safety scrutiny that could limit label growth
Risks to watch — JNJ
- →Stelara biosimilar revenue impact: Stelara generates $9B+ annually but faces US biosimilar competition after patent expiry in 2023 — significant revenue headwind requiring new launches to offset
- →Talc litigation uncertainty: J&J's legal strategy to address talc litigation through subsidiary bankruptcy has faced court challenges — ongoing legal uncertainty creates financial overhang
- →Immunology competition from AbbVie Skyrizi: Tremfya competes with Skyrizi in psoriasis — AbbVie's immunology pipeline is broader and deeper in indications vs J&J's Janssen immunology
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →